Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Population PK/PD study of sugammadex for reversal of rocuronium neuromuscular block in children under 3 years
ChiCTR1900022542Phase 4Recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- Apr 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex and rocuronium in neuromuscular block (NMB) (2 arms), sponsored by Guangzhou Women and Children's Medical Center. Primary endpoints: Muscle relaxant effect, TOF ratio recovery time and 3 more. Started Apr 2019; status: recruiting.
02
Drugs
Sugammadexrocuronium
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR1900022542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022542.